Part I.
Chapter. 1 HSCT: Historical perspective
Storb, R
Chapter. 2 The EBMT: History, present & future
Apperley, J; Gratwohl, A; Mohty, M
Chapter. 3 The donor registries (organization, regulation, international search...)
Madrigal, A; Evseeva, Irina
Chapter. 4 The HSCT Unit (minimal requirements, data manager trasplant coordinator)
Aljurf, M; Niederwieser, Dietger; Rasheed, Walid
Chapter. 5 JACIE accreditation of HSCT programs
Saccardi, R
Chapter. 6
Statistics in HSCT and Cellular Therapies
Labopin, M; Iacobelli, S; de Wreede, Liesbeth; Szydlo, Richard
Part II.
Chapter. 7 Biological properties of HSC: scientific basis for HSCT
Chabannon, C ; Aiuti, M
Chapter. 8 Biological properties of cells other than HSC (adaptative, abT, Treg, DC. Innete gdT, IELs MSC, NK)
Toubert, A; Koehl, U; Bondanza, A
Chapter. 9 Histocompatibility (main concepts on HLA)
K. Fleischhauer; Spierings
Chapter. 10 Clinical & biological concepts for mastering Immune reconstitution after HSCT
Boelens, J; Kuball, J
Part III.
Chapter. 11 Evaluation and counselling of candidates
Rambaldi, A
Chapter. 12 Donor selection for adults and pediatrics
Ayuk, F; Balduzzi, A
Chapter. 13 Conditioning (MAC, RIC, NMA; including TBI)
Nagler, A
Chapter. 14 Bone marrow harvest
Gorin, Claude
Chapter. 15 Mobilization and collection of HSC
Hübel, K
Chapter. 16 Collection of HSC in children
Peters, C; Witt, Volker
Chapter. 17 Processing, cryopreserving, and controlling the quality of HSC
Wuchter, Patrick
Chapter. 18 Procurement and management of cord blood
Rocha, V; Querol, S
Chapter. 19 Graft manipulation
Handgretinger, R
Chapter. 20 Documentation of engraftment and chimerism after HSCT
Bader, P
Chapter. 21 Short and long term controls after HSCT
Shimoni, A
Part IV.
Chapter. 22 Vascular access
Cesaro, S
Chapter. 23 Transfusion support
Schrezenmeier, H
Chapter. 24 Fluid and electrolyte management
Masszi, T; Baumgartner, Annic
Chapter. 25 GVHD prophylaxis (immunosuppression)
Socié, G
Chapter. 26 Management ATG (SIRS)
F. Bonifazi
Chapter. 27 Infections control and isolation procedures
Mikulska, M
Chapter. 28 Pain management
Ahmedzai, SH
Chapter. 29 Specific aspects of management in children
Castagnola, Elio; Riccardi, F
Chapter. 30 Vaccinations
de la Cámara, Rafa
Chapter. 31 Psychological support
Moreno, E ; Schulz-Kindermann, F ; Polomeni, Alice
Chapter. 32 Relevant pharmacological interaction
Bauters, T
Chapter. 33 Role of nursing in HSCT
Babic, A; Murray, J
Chapter. 34 Ethical issues in HSCT
Dalle, JH; El-Ghariani, K
Part V.
Chapter. 35 Quality assessment of life after HSCT for pediatric and adults
Barata, Anna; Jim, Heather
Chapter. 36 Neutropenic fever
Mikulska, M
Chapter. 37 Bacterial infections
Averbuch, D
Chapter. 38 Invasive fungal infections
Maertens, J
Chapter. 39 Viral infections (CMC, EVB, VZV, HSV, HHV6, Resp. V, HCV, HBV…) & anti-viral cell therapy
Ljungman, P; Styczynski, J; Einsele, Hermann
Chapter. 40 Other infections in HSCT (Tuberc, Toxo, PCJ, Noc, List.)
Martino, R
Chapter. 41 Bleeding and thrombotic complications
Savani, B
Chapter. 42 Graft failure
Valcárcel , D; Sureda, A
Chapter. 43 Early complications of endothelial origin
Carreras, E
Chapter. 44 Acute GvHD
Greinix, H; Holler, E; Zeiser, R
Chapter. 45 Chronic GvHD
Wolff, D; Lawitschka, A
Chapter. 46 Post-transplant lymphoproliferative syndromes
Styczynski, J ; Giebel, S
Chapter. 47 Iron overload
Angelucci, E
Chapter. 48 Secondary neoplasia (other than PTLPS)
Tichelli, A
Part VI.
Chapter. 49 Specific organ complications: Ocular / oral / pulmonary / hepatic
Ruutu, T; Hashmi, S
Chapter. 50 Gastrointestinal complications
Basak, G
Chapter. 51 Hemorrhagic cystitis and renal dysfunction
Cesaro, S
Chapter. 52 Pulmonary complications
Carreras, E
Chapter. 53 Neurological complications
Duléry, R
Chapter. 54 Specific organ complications: Skin, hair, musculoskeletal
Ayuk, F; Savani, B
Chapter. 55 Cardiovascular diseases and metabolic syndrome
Snowden, J; Greenfield, D
Chapter. 56 Endocrine, fertility and sexual health
Salooja, N; Shoham, Z; Balduzzi, A
Part VII.
Chapter. 57 Monitoring MRD in ALL
Bader, P; Ossenkoppele, G
Chapter. 58 Preventing/treating relapse with drugs
Kröger, N; Mohty, M
Chapter. 59 Preventing relapse by mean cells (DLI, aBT, subsets, tumour specific T cells)
Kuball, J; Falkenburg, JH Fred; Kolb, HJ; Locatelli, F
Chapter. 60 Cellular therapy (CAR T, TCR T, suicide genes) with management and side effects
Bonini, C; Hudecek, Michael; Fehse, Boris; Bondanza, A
Chapter. 61 Mechanisms of Immune resistance and overcoming immune resistance (checkpoint…)
Dazzi, F; Vago, L
Chapter. 62 Regulatory Aspects of ATMP versus minimally manipulated immune cellsMc Grath, E; Chabannon, C
Part VIII.
Chapter. 63 At-home HSCT
Fernández-Avilés, F
Chapter. 64 Cord blood HSCT (adults & children)
Veys, P; Rocha, V; Sanz, J
Chapter. 65 Haploidentical HSCT (TCD and TC-repleted)
Ciceri, F ; Bacigalupo, A
Chapter. 66 Photopheresis in adults and pediatrics
Greinix, H; Gennery, A
Chapter. 67 Pediatric aspects of haploidentical HSCT
Gennery, A; Bertaina, A; Slatter, M; Lankester, A; Albert, M
Chapter. 68 Overweight and obese patients
Langebrake, C
Chapter. 69 HSCT in Elderly patiens
Duarte, R
Part IX.
Chapter. 70 EBMT indication for allo and auto HSCT
BOARD
Chapter. 71 AML in adults (incl APL)
Nagler, A; Cornelissen, J; Craddock, C; Sanz, MA
Chapter. 72 AML in children
Gibson, B ; Sauer, M
Chapter. 73 ALL in adults
Marks, D ; Stelljes, M
Chapter. 74 ALL in children and adolescents
Peters, C; Locatelli, F; Bader, P
Chapter. 75 Myelodysplastic syndromes
de Witte, T; Robin, M
Chapter. 76 Refractory Anemia and JMML in children
Niemeyer, CM
Chapter. 77 Myelodysplastic/myeloproliferative syndromes
Onida, F; Chalandon, Y
Chapter. 78 Myeloproliferative neoplasms (CML, PM, other MPN)
Olavarria E; Kröger, N
Chapter. 79 Severe aplastic anemia and PNH
Dufour C; Peffault de la Tour, R; Risitano, Antonio Maria
Chapter. 80 Fanconi anemia and other hereditary BMF syndromes
Fioredda, F; Strahm, B; Diaz de Heredia, Cristina; Dalle, JH; Bierings, Marc
Chapter. 81 Hemoglobinopathies (SCA)
